摘要
目的观察益气解毒通络颗粒剂治疗乙肝肝硬化好转的分子机制,完善该方治疗乙肝肝硬化的理论基础。方法随机选择我院体检中心体检健康者15例,肝炎门诊就诊的乙肝肝硬化患者42例,乙肝肝硬化患者均已规范使用抗病毒药恩替卡韦分散片治疗,入组后予益气解毒通络颗粒治疗6个月;对健康者,分别在乙肝肝硬化患者治疗前、治疗6个月后采集血样,待标本集中后采用酶联免疫吸附法成批检测血小板衍生生长因子-AB(PDGF-AB)、血小板衍生生长因子-BB(PDGF-BB)的含量。并将测定结果进行统计分析。结果结果显示,乙肝肝硬化患者血清PDGF-AB水平治疗前较健康者差异显著(<0.01),治疗后较治疗前有所升高(<0.05),但仍低于健康者(<0.05);乙肝肝硬化患者血清PDGF-BB水平治疗前及治疗后与健康者差异显著(<0.01),治疗后较治疗前有所升高,但无统计学意义(>0.05);与治疗前比较,肝功能改善效果明显(<0.05)。结论 PDGF-AB和PDGF-BB水平的变化与乙肝后肝硬化的发病相关,益气解毒通络颗粒能够改善乙肝肝硬化患者血清PDGF-AB和PDGF-BB水平,但对于PDGF-AB的影响更甚。
Objective To observe the molecular mechanism ofYiqi Jiedu Tongluo granules in treatment of post-hepatitis B liver cirrhosis and improve its theoretical basis.Methods 15 healthy persons and 42 patients with post-hepatitis B liver cirrhosis were chosen.The patients with post-hepatitis B liver cirrhosis had been treated by entecavir.Patients with hepatitis B cirrhosis were treated with antiviral drug entecavir dispersible tablets for 6 months,then treated with Yiqi Jiedu Tongluo granules for 6 months.The content of factor-AB (PDGF-AB)and platelet-derived growth factor-BB (PDGF-BB)and the results we.re statistically analyzed.Results The level of serum PDGF-AB was with significant difference between the patients with hepatitis B before treatment and healthy people (P<0.01),and increased after treatment (P<0.05),but still lower than that in healthy people (P<0.05);the levels of serum PDGF-BB in patients with hepatitis B cirrhosis before and after treatment were significantly lower than those in healthy people (P<0.01),and increased after treatment,but the increase was not statistically significant (P>0.05);compared with before treatment,there was significant difference in the improvement of liver function (P<0.01).Conclusion The changes of PDGF-AB and PDGF-BB levels are related to the occurrence of post-hepatitis B cirrhosis.Yiqi Jiedu Tongluo granules can improve the serum levels of PDGF-AB and PDGF-BB in patients with hepatitis B cirrhosis,especially on PDGF-AB.
作者
赫伟丽
苑晓晨
徐光福
赵帆
苏丽双
HE Weili;YUAN Xiaochen;XU Guangfu;ZHAO Fan;SU Lishuang(DongzhimenHospital of Beijing University of Chinese Medicine,Beijing 100700;Institute of Microcirculation, Peking Union Medical College/Chinese Academy of Medical Sciences,Beijing 100005)
出处
《湖北中医药大学学报》
2018年第6期34-37,共4页
Journal of Hubei University of Chinese Medicine
基金
中央高校基本科研业务费专项资金资助
北京中医药大学校级课题(项目编号:2015-JYB-JSMS085)
